Literature DB >> 31305900

CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up.

Scott R Gilles1, Sophia L Yohe1, Michael A Linden1, Michelle Dolan1, Betsy Hirsch1, Bartosz Grzywacz1.   

Abstract

OBJECTIVES: CD161 (NKRP1) is a lectin-like receptor present on NK cells and rare T-cell subsets. We have observed CD161 expression in some cases of T-cell prolymphocytic leukemia (T-PLL) and found it to be useful in follow-up and detection of disease after treatment.
METHODS: Retrospective review of T-PLL cases with complete flow cytometry data including CD161.
RESULTS: We identified 10 cases of T-PLL with flow cytometric evaluation of CD161 available. Six of these cases were positive for CD161 expression. All CD161-positive cases were positive for CD8 with variable CD4 expression, whereas all CD161-negative cases were negative for CD8. In a case with two neoplastic subsets positive and negative for CD8, only the former expressed CD161.
CONCLUSIONS: These novel results suggest that CD161 is often aberrantly expressed in a defined subset of T-PLL positive for CD8. We are showing the utility of this immunophenotype in diagnosis and follow-up. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD161; Flow cytometry; Immunophenotype; NKR-P1A; T-cell lymphoma; T-cell prolymphocytic leukemia

Year:  2019        PMID: 31305900     DOI: 10.1093/ajcp/aqz060

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

Review 1.  CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential.

Authors:  Vanaja Konduri; Damilola Oyewole-Said; Jonathan Vazquez-Perez; Scott A Weldon; Matthew M Halpert; Jonathan M Levitt; William K Decker
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

2.  CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma.

Authors:  Jie Sun; Xiaoquan Zhu; Yanyang Zhao; Qi Zhou; Ruomei Qi; Hui Liu
Journal:  Pharmgenomics Pers Med       Date:  2021-04-01

3.  Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.

Authors:  Wang Di; Wenhua Fan; Fan Wu; Zhongfang Shi; Zhiliang Wang; Mingchen Yu; You Zhai; Yuanhao Chang; Changqing Pan; Guanzhang Li; Ulf Dietrich Kahlert; Wei Zhang
Journal:  Cancer Sci       Date:  2021-12-24       Impact factor: 6.716

4.  Prognostic model based on six PD-1 expression and immune infiltration-associated genes predicts survival in breast cancer.

Authors:  Pan Yuefen; Han Shuwen; Shen Junjun; Wang Yangyanqiu; Zhuang Jing; Pu Jie; Chu Jian
Journal:  Breast Cancer       Date:  2022-03-01       Impact factor: 3.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.